# EDGAR Filing Document

**Accession Number:** 0001403708
**File Stem:** 0001193125-25-321800
**Filing Date:** 2025-12
**Character Count:** 18186
**Document Hash:** beabb77f4d30112cf7522e173663b88a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-321800.hdr.sgml**: 20251217

**ACCESSION NUMBER**: 0001193125-25-321800

**CONFORMED SUBMISSION TYPE**: SC TO-T/A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20251217

**DATE AS OF CHANGE**: 20251217

**GROUP MEMBERS**: QOL-EOS MERGER SUB, INC.

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evoke Pharma Inc
- **CENTRAL INDEX KEY:** 0001403708
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 208447886
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87872
- **FILM NUMBER:** 251577384

**BUSINESS ADDRESS:**
- **STREET 1:** 420 STEVENS AVENUE
- **STREET 2:** SUITE 230
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075
- **BUSINESS PHONE:** 858-345-1494

**MAIL ADDRESS:**
- **STREET 1:** 420 STEVENS AVENUE
- **STREET 2:** SUITE 230
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QOL Medical, LLC
- **CENTRAL INDEX KEY:** 0002093432

**ORGANIZATION NAME:**
- **EIN:** 743030385
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A

**BUSINESS ADDRESS:**
- **STREET 1:** 3405 OCEAN DRIVE
- **CITY:** VERO BEACH
- **STATE:** FL
- **ZIP:** 32963
- **BUSINESS PHONE:** 866-469-3773

**MAIL ADDRESS:**
- **STREET 1:** 3405 OCEAN DRIVE
- **CITY:** VERO BEACH
- **STATE:** FL
- **ZIP:** 32963

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE TO** 

**Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)** 

**of the Securities Exchange Act of 1934** 

**(Amendment No. 2)** 

## EVOKE PHARMA, INC.
**(Name of Subject Company (Issuer))** 

## QOL-EOS MERGER SUB, INC.
**(Offeror)** 

**a wholly owned subsidiary of** 

## QOL MEDICAL, LLC
**(Parent of Offeror)** 

**(Name of Filing Persons (identifying status as offeror, issuer or other person))** 

**Common Stock, $0.0001 par value** 

**(Title of Class of Securities)** 

**30049G302** 

**(CUSIP Number of Class of Securities)** 

**Matthew L. Wotiz** 

**QOL Medical, LLC** 

**3405 Ocean Drive** 

**Vero Beach, Florida 32963** 

**(866) 469-3773** 

**(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)** 

***With Copies to:***

**John C. Connery Jr.** 

**Roland S. Chase** 

**Hill Ward Henderson** 

**101 E. Kennedy Blvd., Suite 3700** 

**Tampa, Florida 33602** 

**(813) 221-3900** 

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ third-party tender offer subject to Rule 14d-1.

☐ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3.

☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☒

If applicable, check the appropriate box(es) below to designate the appropriate rule provisions relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer).

☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer).

------

This Amendment No. 2 to the Tender Offer Statement on Schedule TO (this "**Amendment**") amends and supplements the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission on November 17, 2025, as amended on December 8, 2025 by Amendment No. 1 to Tender Offer Statement on Schedule TO ("**Amendment No. 1**") (as so amended, together with any subsequent amendments or supplements thereto, "**Schedule TO**") by (i) QOL-EOS Merger Sub, Inc., a Delaware corporation ("**Purchaser**") and a direct wholly owned subsidiary of QOL Medical, LLC, a Delaware limited liability company ("**Parent**"), and (ii) Parent. This Schedule TO relates to the offer by Purchaser (the "**Offer**") to purchase all of the outstanding shares of common stock, par value $0.0001 per share (the "**Shares**"), of Evoke Pharma, Inc., a Delaware corporation ("**Evoke**"), at a price of $11.00 per Share, in cash, without interest and subject to any withholding of taxes required by applicable legal requirements. The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated November 17, 2025, and as amended by Amendment No. 1 (as so amended, together with any subsequent amendments or supplements thereto, "**Offer to Purchase**"), and in the related Letter of Transmittal, copies of which are attached as Exhibits (a)(1)(A) and (a)(1)(B) to the Schedule TO, respectively.

This Amendment is being filed solely to amend and supplement items to the extent specifically provided herein. Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO, including all exhibits thereto, remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment. This Amendment should be read together with the Schedule TO. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule TO, as amended by this Amendment.

***Items 1 through 9 and Item 11.***

The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items 1 through 9 and Item 11 incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:

"The Offer expired at one minute past 11:59 p.m., New York City time, on December 15, 2025 (such date and time, the "**Offer Expiration Time**"), and the Offer was not extended. The Depositary has advised that, as of the Offer Expiration Time, a total of 1,164,862 Shares were validly tendered pursuant to the Offer and not validly withdrawn, representing approximately 67.63% of the Shares outstanding as of immediately prior to the Offer Expiration Time.

As of the Offer Expiration Time, the number of Shares validly tendered pursuant to the Offer and not validly withdrawn satisfied the Minimum Condition, and all other conditions to the Offer had been satisfied. Promptly following the Offer Expiration Time, Purchaser irrevocably accepted for payment all Shares validly tendered pursuant to the Offer and not validly withdrawn.

Following acceptance for payment of the Shares, on December 17, 2025, Purchaser effected the Merger in accordance with Section 251(h) of the DGCL, without a meeting of the Company's stockholders and without a vote or any further action by the Company's stockholders.

The Shares ceased to trade on Nasdaq prior to the opening of business on December 17, 2025 and are being delisted. Parent and Purchaser intend to take steps to cause the termination of the registration of the Shares under the Exchange Act and the suspension of all of the Company's reporting obligations under the Exchange Act as promptly as practicable.

On December 17, 2025, Parent issued a press release announcing the expiration and results of the Offer and the consummation of the Merger. The full text of the press release is attached as Exhibit (a)(5)(B) hereto, and incorporated herein by reference."

***Item 12 Exhibits.***

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| (a)(5)(B) | [Press Release issued by QOL Medical, dated December 17, 2025.](d14741dex99a5b.htm) |

---

------

**SIGNATURES** 

After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| **QOL-EOS Merger Sub, Inc.** | **QOL-EOS Merger Sub, Inc.** | **QOL-EOS Merger Sub, Inc.** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By: | /s/ Matthew Wotiz | /s/ Matthew Wotiz |
|  | Name: | Matthew Wotiz |
|  | Title: | Secretary |
| **QOL Medical, LLC** | **QOL Medical, LLC** | **QOL Medical, LLC** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By: | /s/ Matthew Wotiz | /s/ Matthew Wotiz |
|  | Name: | Matthew Wotiz |
|  | Title: | Vice President, Business Development |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: December 17, 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: December 17, 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: December 17, 2025 |

---

## Ex-99.(A)(5)(B)

**Exhibit (a)(5)(B)** 

---

| | |
|:---|:---|
| ![LOGO](g14741dsp04a.jpg) | ![LOGO](g14741dsp04b.jpg) |

---

**Evoke Pharma and QOL Medical Announce Expiration of Tender Offer** 

*Evoke Stockholders Received $11.00 Per Share in Cash* 

SOLANA BEACH, Calif., and VERO BEACH, Fl., December 17, 2025 (GLOBE NEWSWIRE) - Evoke Pharma, Inc. (formerly NASDAQ: EVOK) ("Evoke") and QOL Medical, LLC ("QOL Medical") today announced that the tender offer (the "Offer") by QOL-EOS Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of QOL Medical (the "Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the "Shares"), of Evoke, in exchange for $11.00 in cash per share (the "Offer Price"), subject to any applicable withholding and without interest thereon, expired at one minute past 11:59 p.m., New York City Time, on December 15, 2025 (the "Expiration Time") and was not extended.

Broadridge Corporate Issuer Solutions, LLC, the depositary for the Offer, has advised that, as of the Expiration Time, approximately 1,164,862 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 67.63% of the issued and outstanding Shares immediately prior to the Expiration Time.

Following the consummation of the Offer, Merger Sub merged with and into Evoke (the "Merger"), and all Shares that had not been validly tendered in the Offer were canceled and converted into the right to receive the Offer Price (subject to the exercise of appraisal rights). As a result of the Merger, Evoke became a wholly owned subsidiary of QOL Medical. Prior to the opening of trading on The Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, all shares of Evoke common stock have ceased trading on Nasdaq, and Evoke intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.

**About QOL Medical, LLC** 

QOL Medical is a specialty biopharmaceutical company committed to delivering solutions for rare diseases. Founded in 2003, QOL Medical focuses on improving clinical outcomes and enhancing the quality of life for patients with rare diseases through the acquisition and commercialization of orphan and gastrointestinal products in underserved markets. Learn more at **<u>www.qolmed.com</u>**.

**About Evoke Pharma, Inc.** 

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

------

---

| | |
|:---|:---|
| ![LOGO](g14741dsp04a.jpg) | ![LOGO](g14741dsp04b.jpg) |

---

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.

**About Gimoti<sup>®</sup> (metoclopramide) nasal spray** 

GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information:

WARNING: TARDIVE DYSKINESIA

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The
risk of developing TD increases with duration of treatment and total cumulative dosage.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or
resolve after metoclopramide is stopped.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks
because of the increased risk of developing TD with longer-term use *.* 

GIMOTI is not recommended for use in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as
well as the risk of methemoglobinemia in neonates *.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine
clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.

GIMOTI is contraindicated:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.

------

---

| | |
|:---|:---|
| ![LOGO](g14741dsp04a.jpg) | ![LOGO](g14741dsp04b.jpg) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal
hemorrhage mechanical obstruction, or perforation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a
hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and
bronchospasm.

Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit <u>www.fda.gov/medwatch</u> or call 1-800-FDA-1088.

**Forward-Looking Statements** 

Evoke, QOL Medical and Merger Sub caution you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. The forward-looking statements are based on the parties' current beliefs and expectations and include, but are not limited to: statements regarding the payment and timing of payment of the Offer Price to former Evoke stockholders and the ability and timing of delisting and deregistration of the Shares. The inclusion of forward-looking statements should not be regarded as a representation by Evoke, QOL Medical or Merger Sub that any of their respective plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke's and QOL Medical's businesses and the transactions, including, without limitation: that the timing of the payment or delisting or deregistration may be delayed; and other risks and uncertainties pertaining to Evoke's business, including the risks and uncertainties detailed in Evoke's prior press releases and in the periodic reports it files with the SEC, as well as the tender offer materials filed by QOL Medical and Merger Sub and the Solicitation/Recommendation Statement filed by Evoke in connection with the tender offer.

------

---

| | |
|:---|:---|
| ![LOGO](g14741dsp04a.jpg) | ![LOGO](g14741dsp04b.jpg) |

---

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and none of Evoke, QOL Medical or Merger Sub undertake any obligation to revise or update these statements to reflect events or circumstances after the date hereof, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

**Investor & Media Contact for QOL Medical:** 

Chelsea King

QOL Medical, LLC

Tel: 866-469-3773 x1091

<u>cking@qolmed.com</u>